Bristol-Myers Revenue Rises 8.7%

Bristol-Myers Squibb said first-quarter revenue rose a better-than-expected 8.7%, boosted by the continued expansion of its Opdivo cancer immunotherapy and growth of other key drugs.

from WSJ.com: US Business http://ift.tt/2390XDR
via IFTTT